APPAVISC HV PFS

Since HPMC is an inert substance and does not have any pharmacological action, no evidence suggests that the drug in intraocular milieu bind to APPAVISC HV PFS solution to any significant degree. There is no evidence of drug binding established so far.

APPAVISC HV PFS should be held at room temperature for approximately 30 minutes before use. Protect from freezing and exposure to light. For intraocular use 1.Remove the syringe from its packaging in a sterile environment 2. Open the syringe, withdraw the solution using sterile disposable syringe 3. Open the cannula and firmly screw it onto the lock fitting 4. Depress the plunger and discard the first 0.1 to 0.3 ml of fluid 5. Do not overfill the eye chamber with APPAVISCHV PFS. 6.. At the closing of procedure, irrigate the bulk of the APPAVISCHV PFS out of the anterior chamber with Balanced Salt Solution (BSS).

APPAVISC HV PFS has the risk of IOP elevation. The viscoelastic substances that are not removed from the eye after surgery is not degraded to any significant degree when in the anterior chamber. It obstructs the outflow mainly trabucular meshwork into schlemm’s canal. A spike of IOP is more likely to occur in early hours of surgery(maximum 4-7 hours and often returns to baseline 24 hours). Residual effect of retained Viscoelastic material in anterior chamber should be considered in the differential diagnosis of corneal edema. Severe corneal edema may occur due to thiomersal residues of reused Viscoelastic cannulas. There is a significant cell death at 30 minutes and near complete cell deaths at 2 hours if viscoelastic reused cannulas are used. Severe corneal edema may occur if the contact time of the viscoelastics with corneal endothelium by using reused cannula, following instillation, Additional events occurring includes corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision.